Balaxi Pharmaceuticals — 360° view

Balaxi Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹81 crore and net profit of ₹1.15 crore for the September 2026 quarter.

Balaxi Pharmaceuticals (NSE: BALAXI) closed at ₹33.57 on 20 Nov 2026. Its market capitalisation is ₹185 crore and it trades at 55.0 times earnings.

Share price
₹33.57 (20 Nov 2026)
Market cap
₹185 Cr (20 Nov 2026)
P/E
55.00 (20 Nov 2026)
Revenue
₹81 Cr (September 2026 quarter)
Net profit
₹1 Cr (September 2026 quarter)
ROCE
3.47% (FY26)
ROE
0.59% (FY26)
Book value
₹46.0 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹37.98 / ₹18.70 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: BALAXI

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.